Gyre Therapeutics appoints Ping Zhang to board of directors

Gyre Therapeutics (GYRE) announced the appointment of Ping Zhang to its Board of Directors as the lead independent director of the Board and a member of the Nominating and Corporate Governance Committee of the Board. In addition, Ying Luo, Ph.D. resigned as Chairman and a member of the Board of Directors of Gyre and Gyre Pharmaceuticals, Gyre’s majority indirectly owned subsidiary in the People’s Republic of China, to focus on other responsibilities at GNI Group Ltd. Songjiang Ma has been appointed Chairman of the Board of Directors of Gyre Pharmaceuticals. Zhang has served as a Managing Partner of String Capital Management Co., Limited since 2018.